Pharmaceutical Intermediates CAS 38183-03-8 Raw Material 7, 8-Dihydroxyflavone High Purity

• CAS No.: 38183-03-8
• Formula: C15h10o4
• EINECS: 253-812-4
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Refined
• Model NO.: 7, 8-Dihydroxyflavone
• Colour: Yellow
• Product Name: 7,8-Dihydroxyflavone
• Molecular Formula: C15h10o4
• Molecular Weight: 254.24
• Melting Point: 243-246°c
• Boiling Point: 494.4±45.0 °c(Predicted)
• Density: 1.443±0.06 g/cm3(Predicted)
• Transport Package: Foil Bag
• Specification: 1kg /bag
• Trademark: SENWAYER
• Origin: China
• HS Code: 29349990
• Production Capacity: 2000kg/Month

Product Description

 Pharmaceutical Intermediates CAS 38183-03-8 Raw Material 7,8-Dihydroxyflavone High Purity

Product name	7,8-DIHYDROXYFLAVONE
CAS number	38183-03-8
Molecular formula	C15H10O4
Molecular weight	254.24

Appearance	White powder
Purity	99.0%
Function	7,8-Dihydroxyflavone (7,8-DHF) is a naturally occurring flavone found in Godmania aesculifolia, Tridax procumbens, and primula tree leaves. It has been found to act as a potent and selective small-molecule agonist of the tropomyosin receptor kinase B (TrkB) (Kd ≈ 320 nM), the main signaling receptor of the neurotrophin brain-derived neurotrophic factor (BDNF). 7,8-DHF is both orally bioavailable and able to penetrate the blood-brain barrier. A prodrug of 7,8-DHF with greatly improved potency and pharmacokinetics, R7, is under development for the treatment of Alzheimer's disease.
Description	7,8-Dihydroxyflavone (7,8-DHF) is a naturally occurring flavone found in Godmania aesculifolia, Tridax procumbens, and primula tree leaves. It has been found to act as a potent and selective small-molecule agonist of the tropomyosin receptor kinase B (TrkB) (Kd ≈ 320 nM), the main signaling receptor of the neurotrophin brain-derived neurotrophic factor (BDNF). 7,8-DHF is both orally bioavailable and able to penetrate the blood-brain barrier. A prodrug of 7,8-DHF with greatly improved potency and pharmacokinetics, R7, is under development for the treatment of Alzheimer's disease.

 

7,8-DHF has demonstrated remarkable therapeutic efficacy in animal models of a variety of central nervous system disorders,
including depression, Alzheimer's disease, cognitive deficits in schizophrenia, Parkinson's disease, Huntington's disease,
amyotrophic lateral sclerosis, traumatic brain injury, cerebral ischemia, fragile X syndrome, and Rett syndrome.

7,8-DHF also shows efficacy in animal models of age-associated cognitive impairment and enhances memory consolidation and emotional learning in healthy rodents.

In addition, 7,8-DHF possesses powerful antioxidant activity independent of its actions on the TrkB receptor, and protects against glutamate-induced excitotoxicity, 6-hydroxydopamine-induced dopaminergic neurotoxicity, and oxidative stress-induced genotoxicity.